The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Abstract
Background Whether long-term suppression of replication of hepatitis B virus (HBV) has any beneficial effect on regression of advanced liver fibrosis associated with chronic HBV infection remains unclear. We aimed to assess the effects on fibrosis and cirrhosis of at least 5 years' treatment with tenofovir disoproxil fumarate (DF) in chronic HBV infection.Methods After 48 weeks of randomised double-blind comparison (trials NCT00117676 and NCT00116805) of tenofovir DF with adefovir dipivoxil, participants (positive or negative for HBeAg) were eligible to enter a 7-year study of open-label tenofovir DF treatment, with a pre-specified repeat liver biopsy at week 240. We assessed histological improvement (≥2 point reduction in Knodell necroinflammatory score with no worsening of fibrosis) and regression of fibrosis (≥1 unit decrease by Ishak scoring system).Findings Of 641 patients who received randomised treatment, 585 (91%) entered the open-label phase, and 489 (76%) completed 240 weeks. 348 patients (54%) had biopsy results at both baseline and week 240. 304 (87%) of the 348 had histological improvement, and 176 (51%) had regression of fibrosis at week 240 (p<0·0001). Of the 96 (28%) patients with cirrhosis (Ishak score 5 or 6) at baseline, 71 (74%) no longer had cirrhosis (≥1 unit decrease in score), whereas three of 252 patients without cirrhosis at baseline progressed to cirrhosis at year 5 (p<0·0001). Virological breakthrough occurred infrequently and was not due to resistance to tenofovir DF. The safety profile was favourable: 91 (16%) patients had adverse events but only nine patients had serious events related to the study drug.Interpretation In patients with chronic HBV infection, up to 5 years of treatment with tenofovir DF was safe and effective. Long-term suppression of HBV can lead to regression of fibrosis and cirrhosis.Funding Gilead Sciences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After eradication of HCV infection or viremic suppression in HBV infection, only a long follow-up was able to demonstrate significant regression of liver fibrosis [144,145,146].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [144]
In the citing paper
“Spontaneous fibrosis regression was also observed in patients with hepatitis B virus (HBV) treated with antivirals to suppress HBV activity (255).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [255]
In the citing paper
“which was observed in experimental [12,13] as well as clinical studies [14,15] in numerous diseases (e.g., after alcohol abstinence, in hepatitis C virus (HCV) patients after viral eradication in hepatitis C patients, or even just by a change in lifestyle) [16,17].”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [15]
In the citing paper
“Current therapies mainly focus on treating the underlying etiology, thus preventing disease progression by treating viral hepatitis, advocating alcohol abstinence or a change in life-style.[14,15]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [15]
Citations
Cites
Histological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Singh, R. P., Kurz, J., & Boiteau, G. (1996) · Journal of Virological Methods · doi:10.1016/0166-0934(96)02096-4 · Cited by 2,552
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
Bedossa, P., Dargère, D., & Paradis, V. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.022 · Cited by 2,376
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Panahi, M., Naderi, M., Morteza, T. S., & Parizadeh, S. M. J. (2007) · Cited by 1,722
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
Iloeje, U. H., Yang, H., Su, J., Jen, C., You, S., & Chen, C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.016 · Cited by 1,528
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
Self-citation
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citationGarcia‐Tsao, G., Abraldes, J. G., Berzigotti, A., & Bosch, J. (2017) · Hepatology · doi:10.1002/hep.28906 · Cited by 2,154
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Metadata
- Authors
- Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., Bornstein, J. D., Kitrinos, K. M., Subramanian, G. M., McHutchison, J. G., & Heathcote, E. J.
- Affiliations
- Inserm (FR)
- Auckland City Hospital (NZ)
- Beth Israel Deaconess Medical Center (US)
- Monash Medical Centre (AU)
- Weill Cornell Medicine (US)
- Vanderbilt University (US)
- Aristotle University of Thessaloniki (GR)
- Gilead Sciences (United States) (US)
- University of Toronto (CA)
- Corresponding author
- Marcellin, Patrick
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 381
- Issue
- 9865
- Pages
- 468-475
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2090738619
- Cited by
- 1,788
- References
- 38
- Citations by year
- 2026: 54 · 2025: 99 · 2024: 120 · 2023: 123 · 2022: 137 · 2021: 148 · 2020: 151 · 2019: 136 · 2018: 131 · 2017: 163 · 2016: 142 · 2015: 170 · 2014: 137 · 2013: 71
- FWCI
- 90.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Gilead Sciences
- Genentech
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- tenofovir disoproxil fumarate, chronic hepatitis B, cirrhosis regression, liver fibrosis, antiviral therapy, HBV replication inhibition, long-term treatment safety, histological improvement, virological breakthrough, adefovir dipivoxil, liver biopsy, Knodell score, Ishak score, HBeAg status, drug resistance, adverse events
- MeSH terms
- Tenofovir, Adenine, Adult, Biopsy, Needle, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hepatitis B virus, Humans, Immunohistochemistry, Male, Middle Aged, Severity of Illness Index, Time Factors, Treatment Outcome, Safety Management, Reverse Transcriptase Inhibitors, Hepatitis B, Chronic, Organophosphonates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. https://app.cochat.ai/papers/10.1016/s0140-6736(12)61425-1
- The paper
- Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., Bornstein, J. D., Kitrinos, K. M., Subramanian, G. M., McHutchison, J. G., & Heathcote, E. J. (2013). Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. The Lancet. https://doi.org/10.1016/s0140-6736(12)61425-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.